Page last updated: 2024-10-27

gabapentin and Chronic Kidney Failure

gabapentin has been researched along with Chronic Kidney Failure in 34 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Research Excerpts

ExcerptRelevanceReference
"To compare the effect of gabapentin (GBP) and hydroxyzine (HYDZ) in treating pruritus in patients on dialysis."9.34Comparison of gabapentin and hydroxyzine in the treatment of pruritus in patients on dialysis. ( Ghorghani, M; Hoseininia, S; Mohammadi Kebar, S; Sharghi, A, 2020)
" dexchlorpheniramine in reducing uremic pruritus."9.27Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial. ( Abbade, LP; Gobo-Oliveira, M; Miot, HA; Ogata, MS; Pigari, VG; Ponce, D, 2018)
" Our goal was to compare the effects of gabapentin and pregabalin on improving sleep quality and depression among hemodialysis patients with PPN."9.17Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. ( Atalay, H; Biyik, Z; Gaipov, A; Guney, F; Solak, Y; Turk, S, 2013)
"Gabapentin is an effective agent in treating uremic pruritus."9.14Gabapentin and uremic pruritus in hemodialysis patients. ( Eskandari, D; Ganji, MR; Khashayar, P; Meysamie, AP; Razeghi, E; Togha, M, 2009)
"Our study shows that gabapentin is safe and effective for treating uraemic pruritus in haemodialysis patients."9.11Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. ( Celiker, H; Gunal, AI; Gunal, SY; Kirciman, E; Ozalp, G; Yoldas, TK, 2004)
"We describe a 60-year-old woman who became comatose after a single dose of gabapentin for right-sided sciatalgia."7.73Gabapentin-induced coma in a patient with renal failure. ( Aygen, B; Bektas, S; Berilgen, MS; Dag, S; Dogukan, A; Gunal, AI, 2006)
"Uremic pruritus is one of the most prevalent and bothersome dermatologic symptoms in patients with end-stage renal disease."6.66Gabapentin for uremic pruritus: a systematic review of randomized controlled trials. ( Castillo, RL; Dofitas, BL; Eusebio-Alpapara, KMV, 2020)
"To compare the effect of gabapentin (GBP) and hydroxyzine (HYDZ) in treating pruritus in patients on dialysis."5.34Comparison of gabapentin and hydroxyzine in the treatment of pruritus in patients on dialysis. ( Ghorghani, M; Hoseininia, S; Mohammadi Kebar, S; Sharghi, A, 2020)
" dexchlorpheniramine in reducing uremic pruritus."5.27Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial. ( Abbade, LP; Gobo-Oliveira, M; Miot, HA; Ogata, MS; Pigari, VG; Ponce, D, 2018)
" Our goal was to compare the effects of gabapentin and pregabalin on improving sleep quality and depression among hemodialysis patients with PPN."5.17Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. ( Atalay, H; Biyik, Z; Gaipov, A; Guney, F; Solak, Y; Turk, S, 2013)
"Gabapentin is an effective agent in treating uremic pruritus."5.14Gabapentin and uremic pruritus in hemodialysis patients. ( Eskandari, D; Ganji, MR; Khashayar, P; Meysamie, AP; Razeghi, E; Togha, M, 2009)
"Our study shows that gabapentin is safe and effective for treating uraemic pruritus in haemodialysis patients."5.11Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. ( Celiker, H; Gunal, AI; Gunal, SY; Kirciman, E; Ozalp, G; Yoldas, TK, 2004)
"Despite the acknowledged importance of uremic pruritus to patients, with the exception of gabapentin, the current evidence for treatments is weak."4.95Treatment of Uremic Pruritus: A Systematic Review. ( Askin, N; Bohm, C; Komenda, P; Lerner, B; Rigatto, C; Shaw, J; Simonsen, E; Tangri, N, 2017)
"Gabapentin is an antiepileptic medication that also has been used for restless legs syndrome."3.73Gabapentin-induced myopathy in 2 patients on short daily hemodialysis. ( Lavoie, S; Lipson, J; Zimmerman, D, 2005)
"We describe a 60-year-old woman who became comatose after a single dose of gabapentin for right-sided sciatalgia."3.73Gabapentin-induced coma in a patient with renal failure. ( Aygen, B; Bektas, S; Berilgen, MS; Dag, S; Dogukan, A; Gunal, AI, 2006)
"Uremic pruritus is one of the most prevalent and bothersome dermatologic symptoms in patients with end-stage renal disease."2.66Gabapentin for uremic pruritus: a systematic review of randomized controlled trials. ( Castillo, RL; Dofitas, BL; Eusebio-Alpapara, KMV, 2020)
" The efficacy of MMF as an immunosuppressant and long-term safety in cats of this dosage regimen is unknown."2.61 ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019)
"RLS in end-stage renal disease (ESRD) patients is especially problematic due to premature discontinuation of dialysis and increased mortality."2.55Clinical management of restless legs syndrome in end-stage renal disease patients. ( Jo, J; Mousa, SA; Sahli, ZT; Tarazi, FI, 2017)
"Appropriate dosing of GPs is particularly important to minimize the risk of adverse events in patients of older age, with a history of seizures, or concomitant antipsychotic use."1.72Gabapentinoid dosing and adverse events in patients with chronic kidney disease. ( Cave, B; Hudson, JQ; Washington, K; Wells, DA; Zhu, R, 2022)
"Calciphylaxis is a rare condition usually seen in patients with end-stage renal disease."1.56Pain management in patients with end-stage renal disease and calciphylaxis- a survey of clinical practices among physicians. ( Chinnadurai, R; Lowney, AC; Miller, M; Sinha, S, 2020)
" With 2-L exchanges every 2 hours, we document an apparent elimination half-life of 41."1.46Treatment of Gabapentin Toxicity With Peritoneal Dialysis: Assessment of Gabapentin Clearance. ( Edwards, JC; Ibrahim, H; Oman, Z; Schuelke, M, 2017)
"Gabapentin toxicity was suspected initially in only 41."1.36Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity. ( McKian, KP; Qian, Q; Zand, L, 2010)
" Its normal plasma half-life is 2 - 3 hours; dosage modifications are obligatory in renal insufficiency."1.35Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients. ( Iloanya, PC; Nye, D; Onuigbo, MA, 2009)
"Myoclonus was characterized as multifocal, involving all extremities in the three patients."1.33Gabapentin-induced myoclonus in end-stage renal disease. ( Bell, WL; Glenn, DG; O'Donovan, CA; Zhang, C, 2005)

Research

Studies (34)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's15 (44.12)29.6817
2010's13 (38.24)24.3611
2020's6 (17.65)2.80

Authors

AuthorsStudies
Chen, JJ1
Lee, TH1
Tu, YK1
Kuo, G1
Yang, HY1
Yen, CL1
Fan, PC1
Chang, CH1
Wells, DA1
Washington, K1
Cave, B1
Zhu, R1
Hudson, JQ1
Bobenko, AI1
Heller, S1
Schmitt, N1
Cherdtrakulkiat, R1
Lawung, R1
Nabu, S1
Tantimavanich, S1
Sinthupoom, N1
Prachayasittikul, S1
Prachayasittikul, V1
Zhang, B1
Wu, C1
Zhang, Z2
Yan, K1
Li, C2
Li, Y4
Li, L3
Zheng, C1
Xiao, Y1
He, D1
Zhao, F1
Su, JF1
Lun, SM1
Hou, YJ1
Duan, LJ1
Wang, NC1
Shen, FF1
Zhang, YW1
Gao, ZW1
Li, J5
Du, XJ1
Zhou, FY1
Yin, Z1
Zhu, J2
Yan, D1
Lou, H1
Yu, H1
Feng, C1
Wang, Z1
Wang, Y4
Hu, X1
Li, Z2
Shen, Y1
Hu, D1
Chen, H1
Wu, X1
Duan, Y1
Zhi, D1
Zou, M2
Zhao, Z1
Zhang, X2
Yang, X2
Zhang, J2
Wang, H1
Popović, KJ1
Popović, DJ1
Miljković, D1
Lalošević, D1
Čapo, I1
Popović, JK1
Liu, M1
Song, H2
Xing, Z1
Lu, G1
Chen, D1
Valentini, AM1
Di Pinto, F1
Coletta, S1
Guerra, V1
Armentano, R1
Caruso, ML1
Gong, J1
Wang, N1
Bian, L1
Wang, M1
Ye, M1
Wen, N1
Fu, M1
Fan, W1
Meng, Y1
Dong, G1
Lin, XH1
Liu, HH1
Gao, DM1
Cui, JF1
Ren, ZG1
Chen, RX1
Önal, B1
Özen, D1
Demir, B1
Akkan, AG1
Özyazgan, S1
Payette, G1
Geoffroy, V1
Martineau, C1
Villemur, R1
Jameel, T1
Baig, M1
Gazzaz, ZJ1
Tashkandi, JM1
Al Alhareth, NS1
Khan, SA1
Butt, NS1
Wang, J2
Geng, Y1
Zhang, Y3
Wang, X2
Liu, J2
Basit, A1
Miao, T1
Liu, W1
Jiang, W1
Yu, ZY1
Wu, L2
Qu, B1
Sun, JX1
Cai, AL1
Xie, LM1
Groeneveld, J1
Ho, SL1
Mackensen, A1
Mohtadi, M1
Laepple, T1
Genovesi, S1
Nava, E1
Bartolucci, C1
Severi, S1
Vincenti, A1
Contaldo, G1
Bigatti, G1
Ciurlino, D1
Bertoli, SV1
Slovak, JE1
Hwang, JK1
Rivera, SM1
Villarino, NF1
Li, S1
Cao, G1
Ling, M1
Ji, J1
Zhao, D1
Sha, Y1
Gao, X1
Liang, C2
Guo, Q1
Zhou, C1
Ma, Z1
Xu, J1
Wang, C1
Zhao, W1
Xia, X1
Jiang, Y1
Peng, J1
Jia, Z1
Li, F1
Chen, X2
Mo, J1
Zhang, S2
Li, X1
Huang, T1
Zhu, Q1
Wang, S1
Ge, RS1
Fortunato, G1
Lin, J2
Agarwal, PK1
Kohen, A1
Singh, P1
Cheatum, CM1
Zhu, D1
Hayman, A1
Kebede, B1
Stewart, I1
Chen, G1
Frew, R1
Guo, X1
Gong, Q1
Borowiec, J1
Han, S1
Zhang, M1
Willis, M1
Kreouzis, T1
Yu, K1
Chirvony, VS1
Sekerbayev, KS1
Pérez-Del-Rey, D1
Martínez-Pastor, JP1
Palazon, F1
Boix, PP1
Taurbayev, TI1
Sessolo, M1
Bolink, HJ1
Lu, M1
Lan, Y1
Xiao, J1
Song, M1
Chen, C1
Huang, Q1
Cao, Y1
Ho, CT1
Qi, B1
Wang, Q1
Zhang, W1
Fang, L1
Xie, CL1
Chen, R1
Yang, S1
Xia, JM1
Zhang, GY1
Chen, CH1
Yang, XW1
Domenech-Ximenos, B1
Garza, MS1
Prat-González, S1
Sepúlveda-Martínez, Á1
Crispi, F1
Perea, RJ1
Garcia-Alvarez, A1
Sitges, M1
Kalumpha, M1
Guyo, U1
Zinyama, NP1
Vakira, FM1
Nyamunda, BC1
Varga, M1
Drácz, L1
Kolbenheyer, E1
Varga, F1
Patai, ÁV1
Solymosi, N1
Patai, Á1
Kiss, J1
Gaál, V1
Nyul, Z1
Mosdósi, B1
Valdez, M1
Moosavi, L1
Heidari, A1
Novakovic-Agopian, T1
Kornblith, E1
Abrams, G1
McQuaid, JR1
Posecion, L1
Burciaga, J1
D'Esposito, M1
Chen, AJW1
Samy El Gendy, NM1
Wesolowska, P1
Georg, D1
Lechner, W1
Kazantsev, P1
Bokulic, T1
Tedgren, AC1
Adolfsson, E1
Campos, AM1
Alves, VGL1
Suming, L1
Hao, W1
Ekendahl, D1
Koniarova, I1
Bulski, W1
Chelminski, K1
Samper, JLA1
Vinatha, SP1
Rakshit, S1
Siri, S1
Tomsejm, M1
Tenhunen, M1
Povall, J1
Kry, SF1
Followill, DS1
Thwaites, DI1
Izewska, J1
Kang, JH1
Yoon, Y1
Song, J1
Van de Winckel, A1
Gauthier, L1
Chao, CT1
Lee, YH1
Li, CM1
Han, DS1
Huang, JW1
Huang, KC1
Ni, L1
Güttinger, R1
Triana, CA1
Spingler, B1
Baldridge, KK1
Patzke, GR1
Shen, X1
Wang, B1
Xie, S1
Deng, W1
Wu, D1
Zhang, Q1
Voskamp, BJ1
Peelen, MJCS1
Ravelli, ACJ1
van der Lee, R1
Mol, BWJ1
Pajkrt, E1
Ganzevoort, W1
Kazemier, BM1
Tibrewala, R1
Bahroos, E1
Mehrabian, H1
Foreman, SC1
Link, TM1
Pedoia, V1
Majumdar, S1
Jablonski, CL1
Leonard, C1
Salo, P1
Krawetz, RJ1
Yoon, N1
Hong, SN1
Cho, JG1
Jeong, HK1
Lee, KH1
Park, HW1
Barman, S1
Konai, MM1
Samaddar, S1
Haldar, J1
Mohamed, HSH1
Li, CF1
Hu, ZY1
Deng, Z1
Chen, LH1
Su, BL1
Chu, K1
Liu, YP1
Li, YB1
Zhang, H1
Xu, C1
Zou, Z1
Wu, Z1
Xia, Y1
Zhao, P1
Wang, HT1
de Biase, S1
Pellitteri, G1
Gigli, GL1
Valente, M1
Eusebio-Alpapara, KMV1
Castillo, RL1
Dofitas, BL1
Mohammadi Kebar, S1
Sharghi, A1
Ghorghani, M1
Hoseininia, S1
Waddy, SP1
Becerra, AZ1
Ward, JB1
Chan, KE1
Fwu, CW1
Eggers, PW1
Abbott, KC1
Kimmel, PL1
Chinnadurai, R1
Sinha, S1
Lowney, AC1
Miller, M1
Ibrahim, H1
Oman, Z1
Schuelke, M1
Edwards, JC1
Simonsen, E1
Komenda, P1
Lerner, B1
Askin, N1
Bohm, C1
Shaw, J1
Tangri, N1
Rigatto, C1
Reszke, R1
Szepietowski, JC1
Gobo-Oliveira, M1
Pigari, VG1
Ogata, MS1
Miot, HA1
Ponce, D1
Abbade, LP1
Davison, SN1
Shea, YF1
Mok, MM1
Chang, RS1
Beladi Mousavi, SS1
Zeraati, A1
Moradi, S1
Mousavi, MB1
Mettang, T1
Sahli, ZT1
Jo, J1
Mousa, SA1
Tarazi, FI1
Razeghi, E1
Eskandari, D1
Ganji, MR1
Meysamie, AP1
Togha, M1
Khashayar, P1
Healy, DG1
Ingle, GT1
Brown, P1
Mansfield, AS1
Qian, Q2
Onuigbo, MA1
Nye, D1
Iloanya, PC1
Zand, L1
McKian, KP1
Prieto-Pérez, L1
Montastruc, J1
García-Ruiz, PJ1
Biyik, Z1
Solak, Y1
Atalay, H1
Gaipov, A1
Guney, F1
Turk, S1
Penumalee, S1
Kissner, PZ1
Migdal, SD1
Micozkadioglu, H1
Ozdemir, FN1
Kut, A1
Sezer, S1
Saatci, U1
Haberal, M1
Gunal, AI2
Ozalp, G1
Yoldas, TK1
Gunal, SY1
Kirciman, E1
Celiker, H1
Zhang, C1
Glenn, DG1
Bell, WL1
O'Donovan, CA1
Lipson, J1
Lavoie, S1
Zimmerman, D1
Molnar, MZ1
Novak, M1
Mucsi, I1
Dogukan, A1
Aygen, B1
Berilgen, MS1
Dag, S1
Bektas, S1
Kosmadakis, GC1
Zerefos, N1
Belgrade, M1
Bassilios, N1
Launay-Vacher, V1
Khoury, N1
Rondeau, E1
Deray, G1
Sraer, JD1
Jones, H1
Aguila, E1
Farber, HW1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Treatment Effect of Chinese Medicine Formula on Uremic Pruritus[NCT04650750]Early Phase 160 participants (Anticipated)Interventional2020-12-01Not yet recruiting
Prospective Randomized Study Evaluating the Efficacy of the Spherical Absorptive Carbon AST-120 in Hemodialysis Patients With Uremic Pruritus..[NCT04639674]Phase 4100 participants (Actual)Interventional2020-07-02Completed
Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776]Phase 254 participants (Actual)Interventional2017-08-07Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Prefrontal GABA+ Concentrations

Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition

Interventionmmol/kg (Mean)
N-Acetylcysteine3.90
Gabapentin3.93
Placebo Oral Tablet3.73

Prefrontal Glx Concentrations

Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition

Interventionmmol/kg (Mean)
N-Acetylcysteine21.59
Gabapentin21.69
Placebo Oral Tablet22.25

Reviews

8 reviews available for gabapentin and Chronic Kidney Failure

ArticleYear
Pharmacological and non-pharmacological treatments for restless legs syndrome in end-stage kidney disease: a systematic review and component network meta-analysis.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2022, 09-22, Volume: 37, Issue:10

    Topics: Adult; Dialysis Solutions; Gabapentin; Humans; Kidney Failure, Chronic; Network Meta-Analysis; Renal

2022
    Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227

    Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P

2019
Gabapentin for uremic pruritus: a systematic review of randomized controlled trials.
    International journal of dermatology, 2020, Volume: 59, Issue:4

    Topics: Dizziness; Gabapentin; Humans; Incidence; Kidney Failure, Chronic; Pruritus; Randomized Controlled T

2020
Treatment of Uremic Pruritus: A Systematic Review.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:5

    Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom

2017
Treatment of Uremic Pruritus: A Systematic Review.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:5

    Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom

2017
Treatment of Uremic Pruritus: A Systematic Review.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:5

    Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom

2017
Treatment of Uremic Pruritus: A Systematic Review.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:5

    Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom

2017
End-Stage Renal Disease Chronic Itch and Its Management.
    Dermatologic clinics, 2018, Volume: 36, Issue:3

    Topics: Amines; Analgesics, Opioid; Anticonvulsants; Antipruritics; Chronic Disease; Cyclohexanecarboxylic A

2018
Uremic Itch Management.
    Current problems in dermatology, 2016, Volume: 50

    Topics: Acupuncture Therapy; Amines; Analgesics, Opioid; Anticonvulsants; Calcineurin Inhibitors; Cyclohexan

2016
Clinical management of restless legs syndrome in end-stage renal disease patients.
    CNS spectrums, 2017, Volume: 22, Issue:1

    Topics: Amines; Analgesics, Opioid; Benzodiazepines; Benzothiazoles; Comorbidity; Cyclohexanecarboxylic Acid

2017
Management of restless legs syndrome in patients on dialysis.
    Drugs, 2006, Volume: 66, Issue:5

    Topics: Amines; Anticonvulsants; Benzothiazoles; Clonazepam; Cyclohexanecarboxylic Acids; Dopamine Agents; G

2006

Trials

7 trials available for gabapentin and Chronic Kidney Failure

ArticleYear
Comparison of gabapentin and hydroxyzine in the treatment of pruritus in patients on dialysis.
    Clinical and experimental dermatology, 2020, Volume: 45, Issue:7

    Topics: Administration, Oral; Adult; Anti-Anxiety Agents; Antipruritics; Case-Control Studies; Cross-Over St

2020
Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial.
    European journal of dermatology : EJD, 2018, Aug-01, Volume: 28, Issue:4

    Topics: Aged; Chlorpheniramine; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Gabapentin;

2018
The effect of gabapentin on muscle cramps during hemodialysis: A double-blind clinical trial.
    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2015, Volume: 26, Issue:6

    Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gamma

2015
Gabapentin and uremic pruritus in hemodialysis patients.
    Renal failure, 2009, Volume: 31, Issue:2

    Topics: Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gaba

2009
Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial.
    International urology and nephrology, 2013, Volume: 45, Issue:3

    Topics: Amines; Anti-Anxiety Agents; Calcium Channel Blockers; Cross-Over Studies; Cyclohexanecarboxylic Aci

2013
Gabapentin versus levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study.
    Renal failure, 2004, Volume: 26, Issue:4

    Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dopamine Agonists; Female; Gabapentin;

2004
Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2004, Volume: 19, Issue:12

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans

2004

Other Studies

19 other studies available for gabapentin and Chronic Kidney Failure

ArticleYear
Gabapentinoid dosing and adverse events in patients with chronic kidney disease.
    Clinical nephrology, 2022, Volume: 98, Issue:3

    Topics: Adult; Aged; Antipsychotic Agents; Female; Gabapentin; Humans; Kidney Failure, Chronic; Male; Middle

2022
Concomitant Use of Gabapentinoids with Opioids Is Associated with Increased Mortality and Morbidity among Dialysis Patients.
    American journal of nephrology, 2020, Volume: 51, Issue:6

    Topics: Adult; Aged; Analgesics, Opioid; Cause of Death; Drug Prescriptions; Female; Gabapentin; Hospitaliza

2020
Pain management in patients with end-stage renal disease and calciphylaxis- a survey of clinical practices among physicians.
    BMC nephrology, 2020, 09-18, Volume: 21, Issue:1

    Topics: Acetaminophen; Advance Care Planning; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Analgesic

2020
Treatment of Gabapentin Toxicity With Peritoneal Dialysis: Assessment of Gabapentin Clearance.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:6

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Nephropathies; Diabetic Neuropathies; Fema

2017
Clinical Pharmacology Considerations in Pain Management in Patients with Advanced Kidney Failure.
    Clinical journal of the American Society of Nephrology : CJASN, 2019, 06-07, Volume: 14, Issue:6

    Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Analgesics, Opioid; Carbamazepine; Chronic Pain

2019
Gabapentin-induced myoclonus in an elderly with end-stage renal failure.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2014, Volume: 113, Issue:9

    Topics: Aged; Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobuty

2014
Pregabalin- and gabapentin-associated myoclonus in a patient with chronic renal failure.
    Movement disorders : official journal of the Movement Disorder Society, 2009, Oct-15, Volume: 24, Issue:13

    Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; K

2009
71-year-old man with chronic kidney failure and sudden change of mental status.
    Mayo Clinic proceedings, 2009, Volume: 84, Issue:11

    Topics: Academic Medical Centers; Aged; Amines; Analgesics; Confusion; Cyclohexanecarboxylic Acids; Dose-Res

2009
Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients.
    Advances in peritoneal dialysis. Conference on Peritoneal Dialysis, 2009, Volume: 25

    Topics: Acyclovir; Aged; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; Gabapentin; gamm

2009
Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity.
    The American journal of medicine, 2010, Volume: 123, Issue:4

    Topics: Adult; Age Distribution; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; g

2010
[Myoclonias secondary to gabapentin in a patient with chronic renal failure].
    Revista de neurologia, 2011, Apr-16, Volume: 52, Issue:8

    Topics: Aged; Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Kidney Failu

2011
Gabapentin-induced hypoglycemia in a long-term peritoneal dialysis patient.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003, Volume: 42, Issue:6

    Topics: Acetates; Amines; C-Peptide; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Aci

2003
Gabapentin-induced myoclonus in end-stage renal disease.
    Epilepsia, 2005, Volume: 46, Issue:1

    Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric

2005
Gabapentin-induced myopathy in 2 patients on short daily hemodialysis.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:6

    Topics: Adult; Amines; Anticonvulsants; Atorvastatin; Calcium Channels; Comorbidity; Cyclohexanecarboxylic A

2005
Gabapentin-induced coma in a patient with renal failure.
    Hemodialysis international. International Symposium on Home Hemodialysis, 2006, Volume: 10, Issue:2

    Topics: Administration, Oral; Amines; Coma; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; F

2006
Uremic pruritus.
    The International journal of artificial organs, 2006, Volume: 29, Issue:10

    Topics: Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Capsaicin; Cyclohexanecarboxylic Acids; Gabape

2006
Postherpetic pain control with concomitant illness?
    Postgraduate medicine, 2001, Volume: 109, Issue:3

    Topics: Acetates; Aged; Aged, 80 and over; Amines; Analgesics; Analgesics, Opioid; Biological Availability;

2001
Gabapentin neurotoxicity in a chronic haemodialysis patient.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16, Issue:10

    Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Epilepsy, Absence;

2001
Gabapentin toxicity requiring intubation in a patient receiving long-term hemodialysis.
    Annals of internal medicine, 2002, Jul-02, Volume: 137, Issue:1

    Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Overdose; Female; Gabapentin; g

2002